P044 Treatment benefits of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying non-F508del mutations

Autor:	G. Livnat, A. Dagan, M. Heching, E. Shmueli, M. Gur, M. Cohen-Cymberknoh, M. Shteinberg
Rok vydání:	2022
Předmět:	Pulmonary and Respiratory Medicine Pediatrics Perinatology and Child Health
Zdroj:	Journal of Cystic Fibrosis. 21:S73
ISSN:	1569-1993
DOI:	10.1016/s1569-1993(22)00377-0
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::64aec9d89584b935c637188e9bb8ebb0 https://doi.org/10.1016/s1569-1993(22)00377-0 Zobrazit plný text záznamu Full Text from ScienceDirect